



Supplemental Figures for: Topical endoxifen for mammographic density reduction – a randomized controlled trial Magnus Bäcklund et al.

Supplemental Figure 1. CONSORT Diagram







Supplemental Figure 2. Plasma Z-endoxifen level increase ng/ml per month in the 10 mg and 20 mg arms

Dose

Supplemental Figure 3. Mammographic density change by months of endoxifen exposure in relation to dose of topical endoxifen



Mixed effects linear regression model was used with maximum likelihood handling of missing followup mammographic density measurements. Mammographic density change in the 0 mg arm was beta -0.3 (p=0.12), in the 10 mg arm beta=-0.9% (p=0.04), and in the 20mg arm beta=-1.9% (p=0.03) per month.



Supplemental Figure 4. Risk ratio of severe symptoms¹ in relation to dose of topical endoxifen

¹Risk ratio >1 means more severe symptoms during follow-up compared with baseline.

Vasomotor symptoms were hot flashes, cold sweats, night sweats. Gynecological symptoms were vaginal discharge, itching, bleeding, dryness. Sexual symptoms were intercourse discomfort or lost interest in sex.